S E Rivkin
Overview
Explore the profile of S E Rivkin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
821
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Disis M, Rivkin S, Baron A, Markman M, Connolly D, Ueland F, et al.
Int J Gynecol Cancer
. 2006 May;
16(2):463-9.
PMID: 16681712
Ovarian cancer remains the most lethal gynecological malignancy. The 5th Biennial Symposium overviewed the progress of ovarian cancer research over the last few years. Molecularly based technologies have allowed the...
2.
West H, Crowley J, Vance R, Franklin W, Livingston R, Dakhil S, et al.
Ann Oncol
. 2005 Apr;
16(7):1076-80.
PMID: 15860488
Background: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase...
3.
Dhodapkar M, Jacobson J, Gertz M, Rivkin S, Roodman G, Tuscano J, et al.
Blood
. 2001 Jun;
98(1):41-8.
PMID: 11418461
Current information on Waldenström macroglobulinemia (WM) is based on retrospective or single-institution studies of patients requiring therapy. Between 1992 and 1998, 231 patients with WM were enrolled in a prospective...
4.
Elias L, Lew D, Figlin R, Flanigan R, Thompson M, Triozzi P, et al.
Cancer
. 2000 Aug;
89(3):597-603.
PMID: 10931459
Background: A Phase II trial was conducted to determine the response rate of patients with advanced renal cell carcinoma to a three-drug combination of 5-fluorouracil (5-FU), interleukin-2 (IL-2), and interferon-alpha-2b...
5.
Meyers F, Lew D, Lara Jr P, Williamson S, Marshall E, Balcerzak S, et al.
Invest New Drugs
. 1999 Jul;
16(4):347-51.
PMID: 10426670
Up to 30% of patients with advanced germ cell tumors will fail induction chemotherapy or will relapse. New agents with activity in this still potentially curable subgroup of patients are...
6.
Haas G, Blumenstein B, Gagliano R, Russell C, Rivkin S, Culkin D, et al.
J Urol
. 1999 May;
161(6):1823-5.
PMID: 10332445
Purpose: We ascertained whether combined cisplatin, methotrexate and bleomycin have efficacy for treating locally advanced or metastatic carcinoma of the penis, and evaluate the toxicity resulting from this regimen. Materials...
7.
Rothenberg M, Cox J, DeVore R, Hainsworth J, Pazdur R, Rivkin S, et al.
Cancer
. 1999 Mar;
85(4):786-95.
PMID: 10091755
Background: This multicenter, Phase II trial was performed to evaluate the antitumor activity and toxicity of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma that had recurred or progressed after...
8.
Salmon S, Crowley J, Balcerzak S, ROACH R, Taylor S, Rivkin S, et al.
J Clin Oncol
. 1998 Mar;
16(3):890-6.
PMID: 9508170
Purpose: We evaluated the vincristine, doxorubicin, and dexamethasone (VAD) regimen alone or with chemosensitizers for remission induction and interferon (IFN) versus IFN plus prednisone (IFN/P) for remission maintenance in previously...
9.
Rivkin S, Green S, OSullivan J, CRUZ A, Abeloff M, JEWELL W, et al.
J Clin Oncol
. 1996 Jan;
14(1):46-51.
PMID: 8558219
Purpose: To determine whether the addition of surgical ovariectomy to standard chemotherapy prolongs disease-free survival (DFS) and overall survival in premenopausal patients with estrogen receptor (ER)-positive operable breast cancer with...
10.
Rivkin S, Green S, Metch B, CRUZ A, Abeloff M, JEWELL W, et al.
J Clin Oncol
. 1994 Oct;
12(10):2078-85.
PMID: 7931477
Purpose: To compare chemohormonal therapy, chemotherapy alone, and hormonal therapy alone in postmenopausal patients with estrogen receptor (ER)-positive operable breast cancer and positive axillary nodes with respect to survival and...